Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

This is a study for participants with advanced gastric or gastroesophageal junction adenocarcinoma who have had tumor progression after first-line platinum-contained therapy. The primary study hypotheses are that camrelizumab (SHR-1210) combined with apatinib prolongs overall survival (OS) for participants with tumors that show positive programmed cell death ligand 1 (PD-L1) expression.

Trial Details

NCT ID
NCT04342910
Phase
PHASE3
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • camrelizumab
  • Apatinib Mesylate
  • Paclitaxel
  • Irinotecan
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Histologically- or cytologically-confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma.
  • Confirmed metastatic or locally advanced, unresectable disease.
  • Progression on or after prior first-line therapy containing any platinum/fluoropyrimidine or platinum/taxane doublet.
  • Willing to provide tumor tissue for PD-L1 biomarker analysis.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →